Rethinking Digital Outcome Measures for Amyotrophic Lateral Sclerosis Trials: Consensus Priorities for Actigraphy Harmonization, Validation, and Regulatory Readiness
Journal of Medical Internet Research · 12.11.2026 · 28 · e106677-e106677
DOI: 10.2196/106677 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Internet Research, online erschienen am 12.11.2026. Verfasst von Frederik Steyn und 14 weiteren Autor:innen. Beteiligte Einrichtung: UQ Centre for MND Research, School of Biomedical Sciences, The University of Queensland, Research Road, St Lucia, Brisbane, Queensland, 4072, Austral…. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Actigraphy, Outcome Assessment, Health Care, Clinical Trials as Topic. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Amyotrophic lateral sclerosis (ALS) clinical trials need outcome measures that complement established end points while capturing how people function in daily life. In this viewpoint, we draw on our collective experience in ALS research, clinical trials, digital-measure development, and regulatory science, together with published evidence, a preliminary patient survey, stakeholder discussions, and experience from multisite actigraphy studies. We argue that the field now has a substantial base of longitudinal data and candidate measures, but lacks the coordinated framework needed to compare, prioritize, and validate them across studies. We identify 4 linked priorities: adopt fit-for-purpose measures in stages and within defined contexts of use; harmonize data collection and analysis; use data to shortlist and validate measures across cohorts; and prepare actigraphy methods for trial adoption through early industry and regulatory engagement. Across these priorities, actigraphy should complement rather than replace established clinical outcomes, with its integration guided by patient relevance, ALS phenotypic heterogeneity, participant, and caregiver burden, and the intended context of use. Our central message is that progress now depends less on generating additional isolated datasets or measures than on coordinating the evaluation of existing assets, and aligning future evidence generation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- UQ Centre for MND Research, School of Biomedical Sciences, The University of Queensland, Research Road, St Lucia, Brisbane, Queensland, 4072, Australia, 61 0414653551.
- Ametris, Pensacola, FL, United States.
- North Star ALS, Santa Barbara, CA, United States.
- Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, England, United Kingdom.
- Department of Neurology & Biostatistics, University Medical Center Utrecht, Utrecht, The Netherlands.
- AGH University of Krakow, Krakow, Poland.
Zitieren
APA
Steyn, F., Pilkar, R., Sethi, N., Heller, L., Holdom, C., van Eijk, R. P. A., Straczkiewicz, M., Burke, K. M., Berry, J. D., Chandriani, S., Jewett, G., Hodson-Tole, E., Hovinga, C., Vieira, F., & Guo, C. (2026). Rethinking Digital Outcome Measures for Amyotrophic Lateral Sclerosis Trials: Consensus Priorities for Actigraphy Harmonization, Validation, and Regulatory Readiness. Journal of Medical Internet Research, 28, e106677-e106677. https://doi.org/10.2196/106677
Vancouver
Steyn F, Pilkar R, Sethi N, Heller L, Holdom C, van Eijk RPA, et al. Rethinking Digital Outcome Measures for Amyotrophic Lateral Sclerosis Trials: Consensus Priorities for Actigraphy Harmonization, Validation, and Regulatory Readiness. Journal of Medical Internet Research. 2026;28:e106677-e106677. doi:10.2196/106677
BibTeX
@article{Steyn2026,
author = {Steyn, Frederik and Pilkar, Rakesh and Sethi, Nadia and Heller, Lori and Holdom, Cory and van Eijk, Ruben P A and Straczkiewicz, Marcin and Burke, Katherine M and Berry, James D and Chandriani, Sanjay and Jewett, Gordon and Hodson-Tole, Emma and Hovinga, Collin and Vieira, Fernando and Guo, Christine},
title = {Rethinking Digital Outcome Measures for Amyotrophic Lateral Sclerosis Trials: Consensus Priorities for Actigraphy Harmonization, Validation, and Regulatory Readiness},
journal = {Journal of Medical Internet Research},
year = {2026},
volume = {28},
pages = {e106677--e106677},
doi = {10.2196/106677}
}
EUVIMED